OPEN END TURBO PUT WARRANT - ASTRAZENECA ADR | Market Closed - Börse Stuttgart 12:44:19 25/06/2024 BST | ||
| 1.1 EUR | -5.17% |
|
| Current month | -16.03% | ||
| 1 month | -9.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 1.1 | -5.17% |
| 24/06/24 | 1.16 | -3.33% |
| 21/06/24 | 1.2 | +0.84% |
| 20/06/24 | 1.19 | 0.00% |
| 19/06/24 | 1.19 | +4.39% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 12:44 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | UBS |
| WKN | UM5N9Z |
| ISIN | DE000UM5N9Z5 |
| Date issued | 21/05/2024 |
| Strike | 90.82 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.29 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.4 € |
|---|---|
| Lowest since issue | 0.97 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.68%
- Stock Market
- Certificates
- Certificat
